Abstracts tagged "Anti-CCP"

Abstract Number: 2239 • ACR Convergence 2024
Age, Seropositivity and Inflammation Determine Risk versus Benefit of Endogenous Estrogens on Coronary Atherosclerosis in Rheumatoid Arthritis
George Karpouzas¹, Bianca Papotti², Sarah Ormseth³, Marcella Palumbo², Elizabeth Hernandez³, Matthew Budoff⁴ and Nicoletta Ronda², ¹Harbor-UCLA Medical Center, Torrance, CA, ²University of Parma, Parma, Italy, ³The Lundquist Institute, Torrance, CA, ⁴Harbor-UCLA Medical Center and the Lundquist Institute for Biomedical Innovation, Torrance, CA
Background/Purpose: Endogenous estrogens (E) appear cardioprotective in women in the general population. Yet, proinflammatory effects were described in chronic autoimmune diseases depending on stage, cell-type…
Abstract Number: 2240 • ACR Convergence 2024
Methotrexate Use Influenced the Effect of Inflammation on Cardiovascular Risk Differently in Anticitrullinated Protein Antibody Negative and Positive Patients with Rheumatoid Arthritis
George Karpouzas¹, Piet Van RIel², Elena Myasoedova³, Miguel Angel Gonzalez-Gay⁴, alfonso Corrales-Martínez⁵, Solbritt Rantapaa-Dahlqvist⁶, Petros Sfikakis⁷, Patrick Dessein⁸, Linda Tsang⁹, Carol Hitchon¹⁰, Hani El Gabalawy¹¹, Virginia Pascual Ramos¹², Irazu Contreras Yanez¹³, Iris Jazmín Colunga Pedraza¹⁴, Dionicio Galarza-Delgado¹⁵, jose Ramon Azpiri-Lopez¹⁶, Anne Grete Semb¹⁷, Patrick Durez¹⁸, Durga P Misra¹⁹, Brian Bridal Logstrup²⁰, Ellen Margrethe Hauge²¹, George Kitas²² and Sarah Ormseth²³, and ATACC-RA, ¹Harbor-UCLA Medical Center, Torrance, CA, ²Radboud University Medical Center, Nijmegen, Netherlands, ³Mayo Clinic, Rochester, MN, ⁴University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁶Umeå University, Umeå, Sweden, ⁷Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁸University of Witwatersrand, Johannesburg, South Africa, ⁹University of Witwatersrand, Johanessburg, South Africa, ¹⁰University of Mannitoba, Winnipeg, Canada, ¹¹University of Mannitoba, Winnipeg, MB, Canada, ¹²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico, ¹³Instituto Nacional de las Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹⁴Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁵UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ¹⁶Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁷Diakonhjemmet Hospital, Oslo, Norway, ¹⁸UCLouvain, Louvain, Belgium, ¹⁹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ²⁰University of Aarhus, Aarhus, Denmark, ²¹Aarhus Universitetshospital, Aarhus, Denmark, ²²The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom, ²³The Lundquist Institute, Torrance, CA
Background/Purpose: Disease activity was linked to cardiovascular (CV) risk in rheumatoid arthritis (RA). Anticitrullinated protein antibody (ACPA) positivity associated with greater synovial inflammation, tumor necrosis…
Abstract Number: 0033 • ACR Convergence 2024
Refined Autoantibody Profiles in RA Reveal That Primarily ACPAs Binding Non-glycine Citrulline Motifs Are Associated with Shared Epitope Alleles
Linda Mathsson-Alm¹, Helga Westerlind², Isabel Gehring³, Monika Hansson², Nasim Ghasemzadeh¹, Jessica Rojas-Restrepo³, Saedis Saevarsdottir⁴, Joseph Sexton⁵, Siri Lillegraven⁶, Espen Haavardsholm⁶, Merete Hetland⁷, Hilde Hammer⁸, Tore K. Kvien⁹, Bente Glintborg¹⁰, Leonid Padyukov², Johan Askling² and Caroline Grönwall², and the Danish Rheumatologic Biobank Study Group (the Biomarker Protocol), Swedish Rheumatology Quality Register Biobank Study Group (SRQb), ¹Thermo Fisher Scientific, Uppsala, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Thermo Fisher Scientific, Freiburg, Germany, ⁴University of Iceland, Reykjavik, Iceland, ⁵Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ⁶Diakonhjemmet Hospital, Oslo, Norway, ⁷Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ⁸Diakonhjemmet Hospital, Oslo, Oslo, Norway, ⁹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ¹⁰DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark
Background/Purpose: Carriage of HLA-DRB1 shared epitope (SE) alleles and a history of smoking, have been identified as the most prominent risk factors for development of…
Abstract Number: 2250 • ACR Convergence 2024
Cause Specific Mortality Differs in Rheumatoid Arthritis by Sex and Seropositivity
Elena Joerns¹, Ryan Lennon², Cynthia Crowson², Andrea Lopez-ruiz², Roslin Jose George², Vanessa Kronzer², John Davis² and Elena Myasoedova², ¹Mayo Clinic, Rochester, ²Mayo Clinic, Rochester, MN
Background/Purpose: Persons with rheumatoid arthritis (RA) have an increased risk of mortality compared to the general population. Seropositivity has been shown to be associated with…
Abstract Number: 0035 • ACR Convergence 2024
Anti-CCP Generation in the Female Genital Tract Is Increased During the Postpartum Period in Women Without RA
Daniele Marcy¹, Ashley Visser², Claudia Lugo², Kristin Sturm² and Kristen Demoruelle³, ¹University of Colorado Anschutz Medical Campus, Northglenn, CO, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of Colorado Anschutz Medical Campus, Golden, CO
Background/Purpose: It is well established that women develop RA approximately three times more often than men. In addition, several risk factors for RA uniquely effect…
Abstract Number: 0047 • ACR Convergence 2024
Asthma Is Associated with Increased Serum IgA Antibodies to Citrullinated Peptide Antigenscompared to Healthy Controlsin Discovery and Validation Cohorts
Drayton Rorah¹, Linh Ngo² and Scott Matson³, ¹University of Kansas, Internal Medicine, Kansas City, KS, ²University of Kansas School of Medicine, Kansas City, ³University of Kansas, Kansas City, MO
Background/Purpose: The connection between airway inflammation as seen in patients with asthma and rheumatoid arthritis (RA) has been suggested by previous epidemiologic studies. For instance,…
Abstract Number: 0056 • ACR Convergence 2024
Association of Soluble Immune Checkpoint Proteins with the Risk of Developing RA in ACPA-positive At-risk Individuals
Ryo Motoyama¹, Shohei Nakamura¹, Eisuke Inoue², Hideto Takada³, Masayoshi Harigai⁴ and Yuko okamoto¹, ¹Tokyo Women's Medical University, Tokyo, Japan, ²Showa University, Tokyo, Japan, ³Tokyo Women's Medical University, Denver, CO, ⁴International University of Health and Welfare, Tokyo, Japan
Background/Purpose: ACPA+ individuals without inflammatory arthritis are considered as being in an at-risk state of RA, although further factors are needed to identify individuals with…
Abstract Number: 0158 • ACR Convergence 2024
Rheumatoid Arthritis Testing Patterns by Physicians and Advanced Practice Providers from a National Commercial Laboratory, 2014 – 2023
Karis Lee¹, Min Kyung Lee², David Alfego³, Kristen Clark⁴ and Stanley Naides⁵, ¹Labcorp, Orlando, FL, ²Labcorp, San Diego, CA, ³Labcorp, Carlsbad, CA, ⁴Labcorp, Raleigh, NC, ⁵Labcorp, Dana Point, CA
Background/Purpose: With the commercialization of new diagnostic and monitoring tests for rheumatoid arthritis (RA) and an increasing number of advanced practice providers (APPs) in the…
Abstract Number: 0488 • ACR Convergence 2024
Association of Anti-CarP Levels with Clinical Activity and Serological Profile in Rheumatoid Arthritis
Pablo Martínez Calabuig¹, Elena Grau García², Samuel Leal Rodriguez², Ernesto Tovar Sugrañes³, José Ivorra-Cortés⁴, Carmen Riesco Barcena³, Anderson Huaylla Quispe³, Laura Mas Sánchez⁵, Pablo Muñoz Martínez⁶, Daniel Ramos Castro³, Alba Torrat noves⁷, Iago Alcantara Alvarez⁸, Belén Villanueva Mañés⁸, Miguel Simeo Vinaixa⁸, Andrés Pérez Hurtado³ and Jose A Román-Ivorra⁹, ¹HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, ²HUP La Fe, Valencia, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Spain, ⁴Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, ⁵Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ⁶Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ⁷Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ⁸Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁹Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease where the presence of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (antiCCP) has been associated to…
Abstract Number: 0870 • ACR Convergence 2024
The Impact of Body Mass Index on Cardiovascular Risk in Rheumatoid Arthritis Varies Across Anticitrullinated Protein Antibody Status and Biologic Use
George Karpouzas¹, Elena Myasoedova², Miguel Angel Gonzalez-Gay³, alfonso Corrales-Martínez⁴, Solbritt Rantapaa-Dahlqvist⁵, Petros Sfikakis⁶, Patrick Dessein⁷, Linda Tsang⁸, Carol Hitchon⁹, Hani El Gabalawy¹⁰, Virginia Pascual Ramos¹¹, Irazu Contreras Yanez¹², Iris Jazmín Colunga Pedraza¹³, Dionicio Galarza-Delgado¹⁴, jose Ramon Azpiri-Lopez¹⁵, Anne Grete Semb¹⁶, Piet Van RIel¹⁷, Durga P Misra¹⁸, Patrick Durez¹⁹, Brian Bridal Logstrup²⁰, Ellen Margrethe Hauge²¹, George Kitas²² and Sarah Ormseth²³, and An inTernationAl Cardiovascular Consortium for Rheumatoid Arthritis (ATACC-RA), ¹Harbor-UCLA Medical Center and the Lundquist Institute, Torrance, CA, ²Mayo Clinic, Rochester, MN, ³University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁵Umeå University, Umeå, Sweden, ⁶Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁷University of Witwatersrand, Johannesburg, South Africa, ⁸University of Witwatersrand, Johanessburg, South Africa, ⁹University of Mannitoba, Winnipeg, Canada, ¹⁰University of Mannitoba, Winnipeg, MB, Canada, ¹¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico, ¹²Instituto Nacional de las Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁴UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ¹⁵Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁶Diakonhjemmet Hospital, Oslo, Norway, ¹⁷Radboud University Medical Center, Nijmegen, Netherlands, ¹⁸Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁹UCLouvain, Louvain, Belgium, ²⁰University of Aarhus, Aarhus, Denmark, ²¹Aarhus Universitetshospital, Aarhus, Denmark, ²²The Dudley Group NHS, Birmingham, United Kingdom, ²³The Lundquist Institute, Torrance, CA
Background/Purpose: The impact of body mass index (BMI) as a surrogate of body fat content on cardiovascular (CV) risk in rheumatoid arthritis (RA) is unclear.…
Abstract Number: 1298 • ACR Convergence 2024
What Is an ANA and Why Should I Care? Strategies to Increase Understanding of Basic Rheumatologic Labs Within Medical Education
Megan Schluentz¹ and Sonam Kiwalkar², ¹Ochsner, New Orleans, LA, ²The Vancouver Clinic, Portland, OR
Background/Purpose: A growing availability crisis in Rheumatology requires consideration of steps and best practices that might be employed to meet high demand. Besides increasing the…
Abstract Number: 1326 • ACR Convergence 2024
Which Biomarkers Indicate Imminent Progression to Inflammatory Arthritis in High Risk CCP Positive Persons?
Laurence Duquenne¹, Didem Sahin Eroglu², Jianhua Wu³, Kate Harnden¹, Andrea Di Matteo⁴, Lucy Elizabeth Thornton⁵, Rahaymin Chowdhury⁵, Leticia Garcia-Montoya¹, Kulveer Mankia⁶ and Paul Emery⁶, ¹1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, United Kingdom, ²1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Ankara, Turkey, ³1. University of Leeds, Leeds Institute for Data Analytics, Leeds, United Kingdom 2.Wolfson Institute of Population Health/Queen Mary University of London, UK, Leeds, ⁴1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Jesi, Italy, ⁵1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, ⁶University of Leeds, Leeds, United Kingdom
Background/Purpose: A risk stratification model proposed a simple score using 4 biomarkers to identify those at high risk of developing inflammatory arthritis (IA) in primary…
Abstract Number: 1361 • ACR Convergence 2024
The Effect of Disease Activity on Cardiovascular Risk Varies According to Rheumatoid Factor and Anticitrullinated Protein Antibody Status in Patients with Rheumatoid Arthritis
George Karpouzas¹, Virginia Pascual Ramos², Elena Myasoedova³, Miguel Angel Gonzalez-Gay⁴, alfonso Corrales-Martínez⁵, Solbritt Rantapaa-Dahlqvist⁶, Petros Sfikakis⁷, Patrick Dessein⁸, Linda Tsang⁹, Carol Hitchon¹⁰, Hani El Gabalawy¹¹, Piet Van RIel¹², Irazu Contreras Yanez¹³, Iris Jazmín Colunga Pedraza¹⁴, Dionicio Galarza-Delgado¹⁵, jose Ramon Azpiri-Lopez¹⁶, Anne Grete Semb¹⁷, Durga P Misra¹⁸, Patrick Durez¹⁹, Brian Bridal Logstrup²⁰, Ellen Margrethe Hauge²¹, George Kitas²² and Sarah Ormseth²³, and ATACC-RA, ¹Harbor-UCLA Medical Center, Torrance, CA, ²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico, ³Mayo Clinic, Rochester, MN, ⁴University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁶Umeå University, Umeå, Sweden, ⁷Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁸University of Witwatersrand, Johannesburg, South Africa, ⁹University of Witwatersrand, Johanessburg, South Africa, ¹⁰University of Mannitoba, Winnipeg, Canada, ¹¹University of Mannitoba, Winnipeg, MB, Canada, ¹²Radboud University Medical Center, Nijmegen, Netherlands, ¹³Instituto Nacional de las Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹⁴Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁵UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ¹⁶Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁷Diakonhjemmet Hospital, Oslo, Norway, ¹⁸Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁹UCLouvain, Louvain, Belgium, ²⁰University of Aarhus, Aarhus, Denmark, ²¹Aarhus Universitetshospital, Aarhus, Denmark, ²²The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom, ²³The Lundquist Institute, Torrance, CA
Background/Purpose: Rheumatoid arthritis (RA) activity associates with cardiovascular (CV) risk. Anticitrullinated protein antibodies (ACPA) were linked to higher activity and lower remission rates. Treatment responses…
Abstract Number: 1388 • ACR Convergence 2024
CXC Chemokine Ligand 13 and Rheumatoid Factor as Pharmacodynamic Biomarkers for Abatacept Treatment in Patients with Rheumatoid Arthritis
Ting Wang¹, Ryan Stultz¹, Natalia Giltiay², Christian Lood¹ and Bobby Kwanghoon Han¹, ¹University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, USA, Seattle, WA
Background/Purpose: Abatacept, a CTLA-4-Ig fusion protein, is widely used as a treatment for rheumatoid arthritis (RA). We conducted this study to identify novel predictive and…
Abstract Number: 2210 • ACR Convergence 2024
Comparison of Dual RF and Anti-CCP Seropositive, Single Seropositive, and Seronegative RA on Radiographic Changes, Flares, and Mortality
Rebecca Brooks¹, Sara Achenbach², Vanessa Kronzer¹, Elena Myasoedova¹, Cynthia Crowson¹ and John Davis¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Rochester, MN
Background/Purpose: Both RF and anti-CCP are associated with erosive disease, increased disease activity, and adverse outcomes in RA. However, there have been limited studies investigating how…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].